A New Class of Self-Designing Clinical Trials by Hartung, Joachim
A New Class of Self-Designing Clinical Trials
Joachim HARTUNG
Department of Statistics*, University of Dortmund,
D-44221 Dortmund, Germany
Address:
Department of Statistics
University of Dortmund
D-44221 Dortmund, Germany
Phone: ++49 231 755 3163
Fax: ++49 231 755 5304
Email: Hartung@statistik.uni-dortmund.de
*
and project ’Meta-Analysis in Biometry and Epidemiology’ (SFB 475) of the German Research
Community (DFG)
1A New Class of Self-Designing Clinical Trials
Abstract. A class of self-designing clinical trials is considered which
according to an effective but simple, finite learning algorithm consists
of automatically adaptively planned weighted group sequential trials
with a decision about rejection of the null-hypothesis at each step, but
the full level-α-test at the end of the study preserved.
1. Introduction
In a recent paper [1] self-designing clinical trials are introduced in a general setting for
normal variables with known variances, for which in [2] a concrete proposal for building
the test statistic is given. There the sequence of sample sizes is fixed prior to the beginning
of the study. In [3] based on a general learning scheme completety self-designing trials are
considered, using the inverse normal method, cf. [4], for transforming the p-values
associated with the respective test statistics in the sequential groups.
Here now in defining our easily to handle learning rule for a finite self-designing we
employ the whole prominent family of χ2-distributions to derive our transformations of the
p-values, having desirable properties in our context, cf. [5]. Thus we get a new class of
weighted self-designing trials allowing for sequential decisions about the null-hypothesis,
contrarily to the class discussed above, but also with the full level-α-test at the end of the
trial preserved.
With respect to an early use of p-values and adaptive sample size planning in this
framework let us refer to [6], [7], [8], [9].
22. Basic statistics
For some real valued parameter ϑ we consider the problem of testing at prescribed size α
the hypothesis H vs. H10 0 0: :ϑ ϑ= > , where for example ϑ θ θ= −1 2  if θ1 , θ2 denote the
expectations of the outcome variables of e.g. ’verum’ and ’placebo’, respectively, in a
controlled clinical study.
The study is devided into several, disjoint study parts: stp k( ) , k K= 1, ,K . Upon the
decision rule not all study parts are necessarily carried out.
In stp k( ) let Tk be a one-sided test statistic for testing H0 vs. H1, where large values of Tk
lead to a rejection of H0. Under H0 may Tk have a continuous distribution function Fk ,0 .
Then under H0 the p-value p F T k Kk k k= − =1 10, ( ), , ,K , is uniformly distributed on the
interval (0, 1), and q v F p k Kk k v kk( ) ( ), , ,( )= − =
−
χ 2
1 1 1K , belongs to a (central) χ2-distri-
bution with vk degrees of freedom, where F vkχ 2
1
( )
− denotes the inverse of the χ 2 ( )vk -distri-
bution function, i.e. q vk k( )  is the ( )1− pk -quantile χ 2 1( )vk pk− of the χ 2 ( )vk -distribution,
cf. [4], [5].
For the combined statistic up to stp k( ) thus we get under H0
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Hence in particular, if
S v K k Kk ≥ ∈−χ α2 1 1( ( )) , { , , }Σ for some K ,
so H
o
is rejected at size α, since S SK k≥ , because of q vj j( ) ≥ 0 .
If Tk has under H0 an exact distribution that is only ’nearly continuous’ or if its distribution
is approximated by a continuous distribution function, then the above results hold in a
corresponding good approximation.
Note that for v j = 2 we get by Sk R.A. Fisher’s combining method, cf. [4], [5], [6], [7].
33. Self-designing
At the beginning of the study we decide for a (fictitious) maximum number K of study
parts, stp(k), respectively number K-1 of interim analyses, a minimum number vmin  of
degrees of freedom to be used in a realized stp(k), say vmin = 1 here, and we put v K KΣ ( ) = ,
implying the global critical value: cvα αχ= −2 1( )K .
For a chosen type II error rate β there may exist a sample size spending function
f f T= ( ) such that for the use of the test statistic T by: n f k= −1( , )α β , the minimum
realistic sample size n for a trial is delivered holding the type I and II error rates α and β
conditionally under the knowledge available up to stp k( )− 1 , where stp( )0 stands for the
apriori information.
Further we have to choose a starting configuration of sample size and degrees of
freedom, n v stp1 1 1, ( )in , and a real valued relaxation parameter κ, influencing the
number of study parts to be carried out really.
Let now up to stp(k-1) the test values Tj , respectively pj and qj(vj) , be given, and if
Sk − ≥1 cvα , then H0 is rejected at level α, and the trial stops.
Otherwise the sample size nk and the associated degrees of freedom vk for stp(k) are
determined as follows. Let be
M f F Sk k K v k k= − −− − − −1 1 11 2( ), )( ( ))χ α βΣ (cv ,
i.e. Mk would be that sample size needed for holding α and β in just one further stp by
associating the full remaining degrees of freedom, conditionally under the results obtained
till that time.
But since the parameter estimates involved in the planning function fk-1 may not yet have
stabilized, only a part of Mk should be in general the size of the next stp. We give now a
learning rule that represents an effective but simple way of self-designing.
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then the degrees of freedom to be associated with stp(k) let be given by
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where [ vk* +1] denotes here the largest natural number less than vk* +1. Hence the sample size
of stp(k) may be determined as
n
v
K v k
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,
respectively as the smallest realistic size greater than this value.
The trial stops after stp(k* ) if:
S q v n Mk j
k
j j k k*
*
* *( ) ,= ≥ =
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Σ cv or if: α ; (putting ni = vi = 0 if  k* < i ≤ K).
If Sk* ≥ cvα , we reject H0 at level α, otherwise we stay with H0.
If the sequence of the Mk is not markedly decreasing after some steps the trial may be
stopped. We can also introduce a lower bound for an early acceptance of H0, i.e. if for
example S v kk L≤ χ α
2 ( ( ))Σ , where αL should not be chosen too conservative in order not to
cut paths early that would lead to a rejection of H0, cf. also [2]. Furthermore, the updating
parameter κ can be chosen in dependence on ’k-1’.
The adaptive planning of stp(k) by using information from the previous study parts does
not affect the independence of qk(νk ) and Sk-1 under H0, qk(νk) is in any case χ2(νk)-distributed
under H0; cf. the quite analogous argumentations in [1], [6], [7], [8], [9].
54. Example
Let us consider two medications with binary outcomes, and θ θ1 2, be for instance the
expected cure rates. We are interested in the one-sided test problem: H0: θ θ1 2= vs.
H1: θ θ1 2> .
For the test statistic T in the (2×2)-table analyses of the various study parts we take the
(one-sided) χ2-test, with the p-value p F T= −( ( )) /( )1 22 1χ , as long as for the usual
estimates $ $θ θ1 2> holds, otherwise the one-sided underlying normal test or, of course, in
any case the Fisher-Irwin test can be taken, and sample size calculations for determining Mk
can be done by use of tables or approximate formulas, e.g. [10], [11, p. 418-421], which are
also to find in software packages.
To get a short sequence of study parts the parameters in our example are chosen as
follows: α = 0.025 , β = 0.10 , K = 10 , κ = (k-1) ⋅ 4 , and having no real prior information,
but only a guess that the total number of patients to be involved in the study will lie
between 150 and 250, we take as starting configuration:  n1 = 40 and v1 = 2 in stp(1).
So the weights of the following study parts in form of degrees of freedom are: v2 = 4 ,
v3 = 4 ; i.e. the trial consists really of at most three parts. The global critical value is given
by: cv0.025 = χ2(10)0.975 = 20.5.
Now the trial starts, and we observe in stp(1) the test value of T as: T1 = 1.67, being the
0.8- = (1-2⋅p1)-quantile χ2(1)0.8 of χ2(1), thus: p1 = 0.1 , and q1(2) = χ2(2)0.9 = 4.6 = S1.
Further we extract from stp(1): $ .θ 1 0 7= and $ .θ 2 05= , such that by: cvα - S1 = 15.9
≈ χ2(8)0.95 = Fχ 2 81 095( ) ( . )− , a sample size planning for a one-sided (2×2)-table analysis with a
type I error rate 0.05 and β = 0.1 under assuming the above cure rate estimates yields:
M2 = 222 , or n2 = 112 , (111).
If these estimates for θ θ1 2, stay constant in stp(2), we observe T2 = 4.7 implying:
p2 = 0.015 , q2(4) = χ2(4)0.985 = 12.5 , S2 = 17.1 , and cvα - S2 = 3.4 = χ2(4)0.50 = Fχ 2 41 050( ) ( . )− .
Hence sample size planning as above, however with a type I error rate of 0.50 now, yields:
n3 = M3 = 46.
With the same treatment effects we observe T3 = 1.9 yielding: p3 = 0.08 ,
q3(4) = χ2(4)0.92 = 8.5 , and so: S3 = 25.6 > cv0.025 , i.e. H0 is rejected at level α = 0.025.
6Note that if with a larger treatment difference we had got S2 > 20.5, then the trial had
stopped already after stp(2) with a rejection of H0 at the same level.
We needed about 200 patients to be enclosed in the whole study, assuming an ideal
situation here for demonstrational purpose. In a fixed sample size plan we would have
calculated about 270 necessary patients, if the estimates for the cure rates would have been
known in advance.
Hence, if treatment effects remain nearly stable during the sequence of trials, - otherwise
all designing procedures can come into troubles -, so we can say that our learning method
in designing the trial adaptively uses patients sparingly.
5. Multi-centre trials
Since after stp(k-1) the remaining total number of degrees of freedom is fixed we may also
choose { }v K v kk ∈ − −12 1, , , ( )K Σ under using information from the previous (,- which has
to be assured, of course, e.g. by a fixed rule or by an independent data-monitoring
committee -,) study parts without affecting under H0 the independence of qk and Sk - 1  , or the
distribution of qk , cf. also e.g. [1]. Now in multi-centre trials, for instance, such a case may
occur as follows.
Because of possible centre effects, concomitant variables and organization effort with an
interim analysis, a minimum number n
min , possibly in dependence on k, for the sample size of
stp(k) seems to be useful. So with nk and vk from sec. 3 we may define the modified quantities
by
n
n n n
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respectively the next natural number not greater than K v k− −Σ ( )1 .
Similarly to [2] and [3] also more complicated self-designing rules can be formulated.
With a suitable reformulation, cf. [3], two-sided hypotheses regarding several treatment
arms can be included, too, taking the correct interpretation of the underlying composite
hypothesis into consideration.
76. Concluding remark
We propose a flexible and effective learning method that allows for a completely self-
designing of a group sequential trial, with a decision about rejection of H0 at each step. Due
to its ease of construction it is simple to apply.
The termination of the study is steered by weighting the sequence of sub-trials in form of
choosing different χ2-distributions for transforming the p-values.
Since at the end of the trial a full level-α-test is preserved, the proposed method is
appealing for investigators, who usually are difficult to convince to pay a price for an
interim look, cf. also [6], [7].
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